title: [Immune regulating activity of a novel organoselenium compound ethaselen-1 in C57/BL mice].
abstract: OBJECTIVE
  To detect the Immune regulating activity of ethaselen-1 (Eb1), a novel organoselenium compound, in C57/BL mice transplanted with Lewis lung cancer(LLC).
  
  
  METHODS
  The LLC transplanted C57/BL mice models were established, and the mice was randomly divided into four groups, including high dose Eb1 group (25.0 mg/kg),low dose Eb1 group (12.5 mg/kg), positive control group (levamisole, LMS, 2.0 mg/kg) and negative control group(solvent). Intraperitoneal injections (ip.) of the four pharmaceuticals were performed once a day through the abdominal wall separately, from the second to the eighth day after cancer was transplanted. On the eleventh day, six mice of each group were killed and relative weight of spleen, transforming activity of spleen lymphocytes, NK cell activity, LAK cell activity and percentage of CD4(+)CD8(+)T lymphocyte were detect.
  
  
  RESULTS
  Compared with the control group, high dose Eb1 could obviously increase the relative weight of spleen (150.59% and 122.55%), transforming activity of spleen lymphocytes(162.25% and 561.98%), NK cell activity(78.60% and 219.42%) and percentage of CD4(-)/CD8(+) T lymphocyte(104.72% and 105.87%) in normal mice and LLC mice. Compared with the control group, high dose Eb1 could also increase LAK cell activity of LLC mice by 195.11%.
  
  
  CONCLUSIONS
  The novel organoselenium compound Eb1 has immune regulating activity in vivo.
authors.affiliation: Deparptment of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China.
authors.forename: Yi-rui
authors.initials: YR
authors.lastname: Wang
authors.forename: Jun-jun
authors.initials: JJ
authors.lastname: Xiao
authors.forename: Xiao-min
authors.initials: XM
authors.lastname: Dong
authors.forename: Shu-cong
authors.initials: SC
authors.lastname: Meng
authors.forename: Sheng-ju
authors.initials: SJ
authors.lastname: Deng
authors.forename: Bin
authors.initials: B
authors.lastname: Kuang
authors.forename: Jun
authors.initials: J
authors.lastname: Yan
authors.forename: Fang
authors.initials: F
authors.lastname: Zhao
authors.forename: Hui-hui
authors.initials: HH
authors.lastname: Zeng
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D016516:CD4-CD8 Ratio; D018827:Carcinoma, Lewis Lung / Q000276:immunology* / Q000473:pathology; D045744:Cell Line, Tumor; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D016566:Organoselenium Compounds / Q000494:pharmacology*
chemical_list: D000276:Adjuvants, Immunologic; D016566:Organoselenium Compounds; C529432:ethaselen-1